ADC Therapeutics Funding: $65M Raised, Series A (2023)
ADC Therapeutics has raised $65M in total funding. Latest round: Series A. Backed by Ysios Capital, Gilde Healthcare, Novartis Venture Fund.
ADC Therapeutics funding overview
ADC Therapeutics has raised $65M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in June 2023. The round record for ADC Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Ysios Capital, Gilde Healthcare, Novartis Venture Fund, New Enterprise Associates, Lightstone Ventures, Meneldor and 1 others. 7 distinct backers are named across the disclosed rounds.
ADC Therapeutics has raised $65M in total disclosed funding across the rounds on record.
Who has invested in ADC Therapeutics?
Ysios Capital, Gilde Healthcare, Novartis Venture Fund, New Enterprise Associates, Lightstone Ventures, Meneldor are named among the investors backing ADC Therapeutics.
What was the latest ADC Therapeutics funding round?
The most recent disclosed round is a Series A, announced in June 2023.
Where is ADC Therapeutics based?
No headquarters location is disclosed for ADC Therapeutics.
When did ADC Therapeutics last raise?
The last disclosed ADC Therapeutics round closed in June 2023 at Series A.
ADC Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies below to benchmark round size and investor mix.
